Deaconess Clinic, Inc.

Evansville, Indiana 47725

0 studies enrolling now · 30 studies all time

What they study most

Acne Vulgaris, Actinic Keratoses, Actinic Keratosis, Bladder Neoplasm, Carcinoma in Situ, Cardiovascular Disease, Colorectal Cancer, Diabetes Mellitus, Type 2, Eczema, Food Hypersensitivity, Gastro-Intestinal Tolerance, Gastrointestinal Tolerance

Studies at this site

• Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast — Completed
• BIG Study (Brain, Immune, and Gut Health Evaluation of Infants/Young Children Fed Infant Formula, and Later Supplemental Toddler Nutrition, With 5 Specific HMOs) — Completed
• LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs) — Completed
• Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis — Completed
• Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008) — Completed
• Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial — Completed
• Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: "Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C" — Completed
• Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening "BLUE-C" — Completed
• Dose Range Study of CD5789 in Acne Vulgaris — Completed
• Infant Formula and Toddler Drink Feeding Intervention — Stopped early
• Phase 3 Papulopustular Rosacea Study — Completed
• Growth and Tolerance of Young Infants Fed Infant Formula — Completed
• Growth and Tolerance of Infants Fed Milk-Based Infant Formula — Completed
• Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis — Completed
• A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis — Completed
• Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema — Completed
• Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence — Completed
• An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine — Completed
• A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors — Completed
• Growth and Tolerance of Young Infants — Completed
• Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer — Stopped early
• Behavior of Infants Fed Formula Supplemented With Prebiotics — Completed
• A Study of Degarelix in Patients With Prostate Cancer — Completed
• A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies — Completed
• A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp) — Completed
• A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi-center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne Vulgaris — Completed
• Elemental Formula Hypoallergenicity — Completed
• Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus — Completed
• The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis — Completed
• A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses — Completed